NASDAQ$SAIC

Science Applications International Corporation · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

SAIC's Q4 2021 earnings report was released, demonstrating revenue growth and margin expansion.

SAIC announced Q4 2021 results with revenues of $1.7 billion, an 11% increase year-over-year. Diluted earnings per share were $1.05, and adjusted diluted earnings per share were $1.67. The company's book-to-bill ratio for the quarter was 0.4.

  • Revenues for Q4 2021 increased by 11% to $1.7 billion.
  • Diluted earnings per share for Q4 2021 were $1.05, while adjusted diluted earnings per share were $1.67.
  • Adjusted EBITDA as a percentage of revenues for Q4 2021 was 9.3%.
  • Book-to-bill ratio for the fourth quarter was 0.4.

Headline financials

Total Revenue

$1.72B

Previous: $1.54B+11.5%
EPS (adj)

$1.67

Previous: $1.58+5.7%
Total backlog

$21.5B

Previous: $15.3B+40.5%
Capital Expenditures

$14M

Previous: $7M+100.0%
Free Cash Flow

$39M

Previous: $62M-37.1%
Net Income

$62M

Previous: $60M+3.3%
Operating Income

$102M

Previous: $88M+15.9%
Gross Profit

$200M

Previous: $167M+19.8%
Cash & Equivalents

$171M

Previous: $188M-9.0%
Total Assets

$5.72B

Previous: $4.71B+21.5%
Stock-Based Comp

$12M

Previous: $8M+50.0%

Revenue & EPS history

SAIC · Revenue · Quarterly

$1.72B

Q4 2021+11.5%vs Q4 2020
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Forward guidance

SAIC provided its outlook for fiscal year 2022, including expected impacts from the COVID-19 pandemic. The guidance assumes six months of expected negative COVID-19 impact of between $150 million and $200 million in revenue and approximately $10 million to $15 million in adjusted EBITDA. The guidance also assumes that support currently provided under Section 3610 of the CARES Act continues through the end of fiscal year 2022 (January 28, 2022).

Tailwinds

  • Revenue: $7.1 billion to $7.3 billion
  • Adjusted EBITDA Margin: 8.6% to 8.8%
  • Adjusted Diluted EPS: $6.00 to $6.25
  • Free Cash Flow: $430 million to $470 million
  • Continued support under Section 3610 of the CARES Act

Headwinds

  • Expected negative COVID-19 impact of between $150 million and $200 million in revenue
  • Expected negative COVID-19 impact of approximately $10 million to $15 million in adjusted EBITDA
  • Guidance assumes six months of COVID-19 impact
  • Inherent difficulty in forecasting certain amounts
  • Variability of charges may have an unpredictable and potentially significant impact on future GAAP financial results.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

+0.2%

Avg return

Earnings day

-1.2%

Avg return

5 days after

-0.1%

Avg return

30 days after

54%

31 / 57 earnings

Positive

+16.4%

Q3 2026

Best reaction

-18.4%

Q2 2018

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+1.2%+5.3%+4.7%
Q3 2026+16.4%+11.2%+15.6%
Q2 2026-6.8%-9.9%-10.9%
Q1 2026-13.2%-8.8%+1.7%
Q4 2025+7.2%+1.4%+11.4%
Q3 2025-4.7%-6.4%-7.9%
Q2 2025+3.0%+4.4%+12.7%
Q1 2025-12.9%-14.1%-13.6%
Q4 2024-11.2%-11.3%-12.6%
Q3 2024+9.9%+6.5%+2.9%
Q2 2024-4.5%-3.7%-7.7%
Q1 2024+1.7%+4.2%+11.6%
Q4 2023-0.0%+0.4%-7.0%
Q3 2023+5.4%+1.1%-0.4%
Q2 2023+0.9%+1.0%-2.9%
Q1 2023+7.5%+2.1%+6.7%
Q4 2022-0.7%+1.2%-6.7%
Q3 2022-1.0%-3.3%+1.4%
Q2 2022+3.6%+1.1%+2.2%
Q1 2022+2.5%+0.8%-4.7%
Q4 2021-15.6%-12.0%-7.9%
Q3 2021+3.9%+3.5%+0.5%
Q2 2021+0.5%-0.8%-4.3%
Q1 2021-3.2%-2.2%-14.4%
Q4 2020+6.6%+10.9%+26.6%
Q3 2020+0.5%-1.5%+4.5%
Q2 2020-7.1%-9.0%-5.5%
Q1 2020+8.5%+7.1%+11.0%
Q4 2019+5.0%+3.8%+1.0%
Q3 2019+7.1%+6.7%-1.3%
Q2 2019-10.6%-11.5%-18.6%
Q1 2019-8.5%-9.0%-3.3%
Q4 2018+9.3%+12.9%+17.6%
Q3 2018+9.4%+5.7%+6.7%
Q2 2018-18.4%-16.9%-7.3%
Q1 2018-3.3%-7.9%-6.1%
Q4 2017-13.7%-14.4%-15.4%
Q3 2017+8.0%+3.4%+4.2%
Q2 2017+1.8%+1.8%+4.6%
Q1 2017+1.2%-2.1%+4.6%
Q4 2016+12.3%
Q3 2016-0.9%
Q2 2016-12.3%
Q1 2016-4.5%
Q4 2015-6.2%
Q3 2015+2.5%
Q2 2015+1.7%
Q1 2014+12.1%
Q1 2015+12.1%
Q4 2012+7.8%
Q1 2013+7.8%
Q4 2014+10.2%
Q3 2013-7.9%
Q3 2014-5.4%
Q4 2013-0.4%
Q2 2014-0.4%
Q2 2013-0.4%
Q3 2012
Q2 2012
Q1 2012
Q4 2011
Q3 2010

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro